Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SOUNDTRACK-D2
CTR20260131Phase 3Active
- Sponsor
- AstraZeneca
- Start
- Apr 2026
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of surovatamig in diffuse large B-cell lymphoma (DLBCL), sponsored by AstraZeneca. Started Apr 2026; status: active.
02
Drugs
surovatamig
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on CTR20260131.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260131.